Advice
Following a full re-submission Atomoxetine (Strattera) is accepted for restricted use within NHS Scotland for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older or in adolescents. It is restricted to use in patients who do not respond to stimulants or in whom stimulants are contraindicated or not tolerated. It is restricted to use by physicians with appropriate knowledge and expertise in treating ADHD. This advice concerns use in children and adolescents only and does not cover use in adults. Atomoxetine (Strattera) it is not a Controlled Drug under the Misuse of Drugs regulations 2001.
Download detailed advice55KB (PDF)
Medicine details
- Medicine name:
- Atomoxetine (Strattera®)
- SMC ID:
- 153/05
- Indication:
- Attention-Deficit/Hyperactivity Disorder
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Superseded
- Date advice published
- 11 July 2005